NME Outlook: Diabetes Drugs May Be Head Of The Class In 2005
Executive Summary
The coming year could bring three significant approvals for novel classes of diabetes drugs: Amylin's Symlin, Lilly/Amylin's exenatide and Bristol-Myers Squibb/Merck's muraglitazar
You may also be interested in...
Amylin/Lilly Byetta Clears FDA As Adjunct Diabetes Therapy; Launch Is June
Amylin and Lilly will launch the incretin mimetic Byetta (exenatide) for the adjunctive treatment of type 2 diabetes June 1
Amylin/Lilly Byetta Clears FDA As Adjunct Diabetes Therapy; Launch Is June
Amylin and Lilly will launch the incretin mimetic Byetta (exenatide) for the adjunctive treatment of type 2 diabetes June 1
NDA Filings Drop In 2004: Latest Sign Of Concern For R&D Productivity
The pharmaceutical industry is continuing to face declining output from its R&D investment